Author:
Sharma Manish,Farough Samira,Burkett Andre,Prasanth Jerome,El-Shafeey Nabil,Zygadlo Dominic,Dunn Chera,Korn Ron
Reference20 articles.
1. Walovitch R, Memisoglu A, Walsh D. WorldCare Clinical. Adjudication in Oncology Trials: A Concept Whose Time Has Come. PharmaNet Development Group, Inc, USA. http://docplayer.net/20368734-Adjudication-in-oncology-trials-a-concept-whose-time-has-come.html
2. Monitoring Reader Metrics in Blinded Independent Central Review of Oncology Studies
3. Adjudication Rates between Readers in Blinded Independent Central Review of Oncology Studies;Ford;J Clin Trials,2016
4. United States Food and Drug Administration Guidance for Industry: Clinical trial endpoints for the approval of cancer drugs and biologics. Rockville, MD: US Department of Health and Human Services; 2007.
5. Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?